Skip to main content
Smart Investors Daily
ON

NASDAQ · ONCY

Oncolytics Biotech Inc.

Healthcare · Biotechnology

$0.35

Down-$0.04 (-10.37%)

Updated Nov 21, 2026, 5:20 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
100.06M
P/E ratio
-3.94
Dividend yield
0.00%
52-week range
$0.33 – $1.30
Volume
1.11M
Avg. volume
891.91K

Price performance · ONCY

ONCY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

ONCY closed at $0.35 after 21 trading sessions, down 30.30% for the selected period.

Last close
$0.35
Period change
-30.30%
Period low
$0.34
Period high
$0.50
Daily close
View OHLC price history
ONCY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$0.38$0.3885$0.34$0.35011.11M
Nov 19, 2026$0.4434$0.46$0.39$0.39061.7M
Nov 18, 2026$0.3899$0.4454$0.3765$0.44032.19M
Nov 17, 2026$0.3336$0.3933$0.3334$0.38251.59M
Nov 16, 2026$0.371$0.3763$0.337$0.33991.33M
Nov 13, 2026$0.3834$0.3896$0.3363$0.371.26M
Nov 12, 2026$0.4128$0.42$0.3682$0.372818.34K
Nov 11, 2026$0.398$0.4191$0.3669$0.41161.5M
Nov 10, 2026$0.4113$0.4176$0.3815$0.3818545.2K
Nov 9, 2026$0.45$0.46$0.3829$0.40771.14M
Nov 6, 2026$0.4551$0.461$0.4282$0.4394516.95K
Nov 5, 2026$0.43$0.457$0.3841$0.44882.86M
Nov 4, 2026$0.4101$0.4442$0.3949$0.4248873.74K
Nov 3, 2026$0.40$0.4072$0.3816$0.39554.44K
Nov 2, 2026$0.4237$0.4255$0.394$0.40847.95K
Oct 30, 2026$0.4207$0.4299$0.405$0.4254764.33K
Oct 29, 2026$0.44$0.45$0.425$0.4277607.28K
Oct 28, 2026$0.46$0.4631$0.43$0.44162.19M
Oct 27, 2026$0.4703$0.4998$0.4601$0.4623859.33K
Oct 26, 2026$0.51$0.52$0.47$0.4732711.69K
Oct 23, 2026$0.505$0.5077$0.49$0.5023376.01K

Latest ONCY news

The latest Smart Investors Daily articles mentioning ONCY.

ONCY research

Overview

Company profile and research snapshot.

Company profile

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ONCY recent ratings
DateFirmRatingTarget
Aug 12, 2025H.C. WAINWRIGHT & CO., LLCBuy—
Aug 11, 2025H.C. WAINWRIGHT & CO., LLCBuy—
Aug 8, 2025JONES TRADINGHold—
Aug 7, 2025JONES TRADINGHold—
Jul 9, 2025LEEDE JONES GABLEBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 16, 2026

ONCY: Supply Agreement with Coherus to Evaluate Pelareorep in SCAC with Checkpoint Inhibitor

By David Bautz, PhD NASDAQ: ONCY READ THE FULL ONCY RESEARCH REPORT Business Update Clinical Supply Agreement with Coherus for SCAC Trial On November 11, 2026, Oncolytics Biotech, Inc. (NASDAQ: ONCY) announced a clinical supply agreement with Coherus Oncology, Inc. in which Coherus will supply LOQTORZI ® (toripalimab-tpzi) a next-generation PD-1 inhibitor, for use in a planned clinical study in

Yahoo · Nov 13, 2026

Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC

Pelareorep and toripalimab combine potentially complementary mechanisms designed to enhance antitumor immune responses and help overcome tumor immune resistance Study may represent a first step toward evaluating the combination more broadly across HPV-associated cancers SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, announced today that it has entered into a clinic

Yahoo · Nov 9, 2026

Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients

Single-cell sequencing demonstrates pelareorep’s ability to remodel the tumor microenvironment in a hematological cancerSAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced translational data in heavily pretreated relapsed/refractory multiple myeloma patients, which will be presented at the 68th American Society of Hematology (“ASH”) Annual Meeting and Ex

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.